The Hematologist

In this episode, Contributing Editor Lauren Pommert, MD, a pediatric oncologist specializing in children with leukemia at Cincinnati Children's in Cincinnati, Ohio, talks with Natalie DelRocco, PhD, a senior statistician for the Children’s Oncology Group’s Bone Tumors Committee and an assistant professor of clinical population and public health sciences in the Division of Biostatistics at the University of Southern California in Los Angeles. They talk about a recent paper co-authored by Dr. DelRocco: “Enhanced Risk Stratification for Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia: A Children’s Oncology Group Report.”

In this episode, Contributing Editor Tycel Phillips, MD, an associate professor of medicine and a hematologist-oncologist at City of Hope Medical Center in Duarte, California, talks with Martin Dreyling, MD, a professor of medicine and head of the lymphoma program at LMU Hospital in Munich. They discuss the TRIANGLE trial, conducted by Dr. Dreyling and colleagues, for the European Mantle Cell Lymphoma Network. 

In this episode, Contributing Editor Surbhi Shah, MD, a classical hematologist at Mayo Clinic in Phoenix, leads a conversation about anticoagulation stewardship. Her guests are Allison Burnett, PharmD, PhC, an antithrombosis stewardship pharmacist at the University of New Mexico Hospital and president of the Anticoagulation Forum, and Geoffrey Barnes, MD, MSc, an associate professor and vascular medicine specialist at the University of Michigan and president-elect of the Anticoagulation Forum.

In this episode, Editor-in-Chief Shaji Kumar, MD,  a professor of medicine at Mayo Clinic in Rochester, Minnesota, talks with Jorge Cortes, MD, the inaugural editor-in-chief of Blood Global Hematology, one of the latest additions to the growing Blood journals portfolio. Dr. Cortes, director of the Georgia Cancer Center at Augusta University, shares his vision for the journal and his thoughts on how it will impact the hematologic research community around the world. Support for this episode provided by Rigel Pharmaceuticals.

In this episode, Contributing Editor Lori Muffly, MD, MS, an associate professor of medicine specializing in blood and marrow transplantation and cellular therapy at Stanford University in California, talks with Fred Appelbaum, MD, executive vice president and deputy director at the Fred Hutchinson Cancer Center in Seattle, and a professor of medicine in the division of hematology and oncology at the University of Washington. They talk about Dr. Appelbaum’s book, Living Medicine: Don Thomas, Marrow Transplantation, and the Cell Therapy Revolution.

In this episode, Contributing Editor Bethan Psaila, MD, PhD, an associate professor of hematology at the University of Oxford’s MRC Weatherall Institute of Molecular Medicine, talks with Andrew Dunbar, MD, an assistant professor and independent lab investigator at MD Anderson Cancer Center in Houston, Texas. They discuss Dr. Dunbar’s paper recently published in Cancer Discovery: “JAK2V617F reversible activation shows its essential requirement in myeloproliferative neoplasms.”

In this episode, Contributing Editor Samuel Wilson, MD, an assistant professor of hematology at the University of North Carolina, Chapel Hill, talks with Marc Blondon, MD, an attending physician in the division of angiology and hemostasis with the University Hospitals of Geneva (Switzerland). They talk about a paper co-authored by Dr. Blondon titled, “Longitudinal profile of estrogen-related thrombotic biomarkers after cessation of combined hormonal contraceptives.” Dr. Wilson wrote about the study in a recent issue of The Hematologist.

In this episode, Editor-in-Chief Shaji Kumar, MD, a professor of medicine at Mayo Clinic in Rochester, Minnesota, talks with Leslie Ellis, MD, a professor of internal medicine at Atrium Health Wake Forest Baptist in Winston Salem, North Carolina. They discuss the ASH Ambassador Program, which is designed to support the recruitment and retention of trainees into hematology. Dr. Ellis is chair of an ASH oversight subcommittee for that program.

In this episode, Tamara Dunn, MD, a clinical associate professor of medicine in the division of hematology at Stanford University in Stanford, California, and co-chair of ASH’s Women in Hematology Working Group, hosts a conversation with Toyosi Onwuemene, MD, an associate professor of medicine, specializing in hemostasis/thrombosis, at Duke University in Durham, North Carolina, and Nina Shah, MD, the global clinical head for multiple myeloma research and development at AstraZeneca. They talk about career choices and opportunities for women in hematology, both in academic medicine and industry. Support for this episode provided by Sanofi.

In this episode, Contributing Editor Ajai Chari, MD, a professor of clinical medicine and director of the myeloma program at the University of California San Francisco, talks with Pieter Sonneveld, MD, PhD, a professor of hematology at the Erasmus University of Rotterdam in the Netherlands. They discuss Dr. Sonneveld’s recent paper, “Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma,” published in The New England Journal of Medicine. Dr. Chari wrote about Dr. Sonneveld’s paper in The Hematologist with his Diffusion article, “Four Is Better Than Three: Will We Finally Agree?” 

Disclosures: Dr. Chari has received consulting fees from Abbvie, Adaptive, Amgen, Antengene, Bristol Myers Squibb, Forus, Genentech/Roche, Glaxo Smith Klein, Janssen, Karyopharm, Millenium/Takeda, and Sanofi/Genzyme and received research funding from Janssen. Dr. Sonneveld has served on the advisory board of Pfizer and has received research funding and served on the advisory boards of Amgen, Bristol Myers Squibb, Celgene, Janssen, and Karyopharm.

Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/